Women's Concerns

  • As a breast cancer survivor, I've been told that I cannot take Sprycel® (Dasatinib) as it may increase the chance of my breast cancer recurring. Is this so?

    There is no apparent concern for breast cancer survivors taking Sprycel® (Dasatinib) - neither proven, nor theoretical.  There is no known data to support the claim that the drug cannot be utilized by breast cancer survivors.  In fact, the drug has been utilized in trials for patients living with triple-negative breast cancer, based on the drug's SRC inhibitory properties. 

    Note: Links to sources outside the Ask the CML Experts™ portal or the National CML Society, are provided as a convenience to our readers.  These resources have not been reviewed by our panel of experts and therefore no representation is made to the quality or soundness of the information.

    Sprycel® is a registered trademark of Bristol-Myers Squibb

  • My partner has just been diagnosed with CML, is taking Gleevec, and is concerned about having sex without a condom. Is there any type of risk for me due to the drug being in his system??

    There is no indication that Gleevec® poses a risk to a partner during sexual activity.  As a pre-caution, Gleevec® tablets should not be handled by individuals that do not have CML, however, once taken, the drug has no affect on others through physical contact.

    For those where pregnancy is not an issue, for example in individuals who have had reproductive surgeries to prevent pregnancy, Gleevec® poses no risk to a partner engaged in unprotected sexual activity. The drug is not passed through physical contact or bodily fluids.

  • Is breast tenderness related to CML therapy with TKIs (Tyrosine Kinase Inhibitors)?

    Yes, one or both breasts can become tender to touch while taking tyrosine kiinase inhibitors. This condition is not limited to women. Men may experience this as well. It is important to let your health care provider know about this symptom if you experience it. There are other conditions that can include breast tenderness as a symptom, and these conditions may be serious or may impact your CML care. In general, breast tenderness does not require a change in choice or dose of your CML medication. Many women choose to perform breast self-examinations (BSE), especially if they experience breast tenderness. These self-assessments allow you to become familiar with your own skin and breast tissue, and more easily recognize when changes occur. You can find more informatio about the option of breast self-examinations at this link: http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-detection. If at any time, you experience a discharge from your nipples, reddened or warm areas around the breast, or other unusual symptoms, notify your health care provider as soon as possible.

    Note: Links to sources outside the Ask the CML Experts™ portal or the National CML Society, are provided as a convenience to our readers.  These resources have not been reviewed by our panel of experts and therefore no representation is made to the quality or soundness of the information.